Chief Operating Officer: An Outlook on Work & Life
Tu Diep, Skye Bioscience's COO, discusses value and his perspective on making a positive contribution.
Expert Panel with Skye CEO + Obesity Specialist
South by Southwest panel with CEO Punit Dhillon and Clinical Advisor Beverly Tchang, MD, discusses need for sustainable weight loss, emerging advancements, combination therapies, and possibilities for CB1 inhibition.
SXSW 2025 Pre-panel Chat Covers Broad Obesity-related Topics
Skye CEO Punit Dhillon and Clinical Advisory Board Member Dr. Beverly Tchang, MD, chat about SXSW 2025 and weight loss ahead of their panel, “Weighing in on Weight Loss.”
COO Reflects on the Challenges and Path of His Journey
Tu Diep, Skye Bioscience's COO, discusses his lifelong passion, interest and work leading into the drug development journey of lead asset nimacimab.
The Understanding & Treatment of Obesity is Evolving
Skye Bioscience clinical advisor Dr. Beverly Tchang, MD, an endocrinologist and obesity medicine specialist, offers wide-ranging insights into the challenges of obesity and the evolving approaches to this condition.
The Maturing Specialty of Obesity Management
Skye Bioscience clinical advisor Dr. Rekha Kumar, MD, MS, an endocrinologist and obesity medicine specialist, offers perspectives regarding the condition of obesity and treatment barriers and opportunities.
Business of Biotech Podcast: Potential for Antibody CB1 Inhibitor
A discussion of the merits of an antibody-based CB1 inhibitor, potential lack of neuropsychiatric side effects, and potential role of a CB1 inhibitor in the realm of weigh loss therapeutics.
Empowered Patient Podcast: Discussing Fat Metabolism
CEO Punit Dhillon discusses the potential to shift the weight-loss paradigm from primarily caloric restriction to more broadly address underlying issues related to fat metabolism.